December 20 Product: Novo Nordisks Alhemo Indication: Adults and children aged 12 and up with hemophilia A or B Following an FDA rejection last year, Novo Nordisks Alhemo has received the regulators greenlight for preventing bleeding episodes or reducing their frequency in adults and children aged 12 and up with hemophilia A or B who have developed inhibitors, which are antibodies that neutralize clotting factors such as factor VIII or factor IX
Allosteric modulators of NMDA receptors: multiple sites and mechanisms
doi:10.1074/jbc.M114.571521
These effects, observed in animal models, have been linked to improvements in muscle physiology and cardiac performance
The US Olympic Committee tested them and confirmed they contained no banned substances, stimulants, or drugs of any kind
Individuals who passed the initial screening were invited to visit the clinic, where they provided informed consent and underwent a comprehensive eligibility screening